Loading...

We've got a brand new version of Simply Wall St! Try it out

Bruker

Nasdaq:BRKR
Snowflake Description

Outstanding track record with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BRKR
Nasdaq
$7B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
BRKR Share Price and Events
7 Day Returns
1.6%
NasdaqGS:BRKR
-1.5%
US Life Sciences
0.3%
US Market
1 Year Returns
48.1%
NasdaqGS:BRKR
14.1%
US Life Sciences
12.5%
US Market
BRKR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bruker (BRKR) 1.6% 10.5% 21.6% 48.1% 109.6% 164.7%
US Life Sciences -1.5% 2.2% 2.1% 14.1% 83.2% 115.6%
US Market 0.3% 4.1% 5.6% 12.5% 39.4% 44.7%
1 Year Return vs Industry and Market
  • BRKR outperformed the Life Sciences industry which returned 14.1% over the past year.
  • BRKR outperformed the Market in United States of America which returned 12.5% over the past year.
Price Volatility
BRKR
Industry
5yr Volatility vs Market

BRKR Value

 Is Bruker undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Bruker to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Bruker.

NasdaqGS:BRKR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:BRKR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.02
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.022 (1 + (1- 21%) (7.92%))
1.057
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.06
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.057 * 5.96%)
9.03%

Discounted Cash Flow Calculation for NasdaqGS:BRKR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Bruker is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGS:BRKR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.03%)
2020 308.00 Analyst x1 282.49
2021 316.00 Analyst x1 265.82
2022 323.81 Est @ 2.47% 249.82
2023 332.06 Est @ 2.55% 234.97
2024 340.71 Est @ 2.6% 221.12
2025 349.71 Est @ 2.64% 208.16
2026 359.04 Est @ 2.67% 196.01
2027 368.68 Est @ 2.69% 184.60
2028 378.63 Est @ 2.7% 173.88
2029 388.89 Est @ 2.71% 163.80
Present value of next 10 years cash flows $2,180.00
NasdaqGS:BRKR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $388.89 × (1 + 2.73%) ÷ (9.03% – 2.73%)
$6,339.80
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $6,339.80 ÷ (1 + 9.03%)10
$2,670.25
NasdaqGS:BRKR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,180.00 + $2,670.25
$4,850.25
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,850.25 / 153.99
$31.5
NasdaqGS:BRKR Discount to Share Price
Calculation Result
Value per share (USD) From above. $31.50
Current discount Discount to share price of $48.34
= -1 x ($48.34 - $31.50) / $31.50
-53.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Bruker is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bruker's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bruker's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:BRKR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $1.33
NasdaqGS:BRKR Share Price ** NasdaqGS (2019-11-12) in USD $48.34
United States of America Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 32.14x
United States of America Market PE Ratio Median Figure of 2,922 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bruker.

NasdaqGS:BRKR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BRKR Share Price ÷ EPS (both in USD)

= 48.34 ÷ 1.33

36.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bruker is overvalued based on earnings compared to the US Life Sciences industry average.
  • Bruker is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does Bruker's expected growth come at a high price?
Raw Data
NasdaqGS:BRKR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 36.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
14.3%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.53x
United States of America Market PEG Ratio Median Figure of 2,023 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

NasdaqGS:BRKR PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 36.46x ÷ 14.3%

2.55x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bruker is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Bruker's assets?
Raw Data
NasdaqGS:BRKR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $5.49
NasdaqGS:BRKR Share Price * NasdaqGS (2019-11-12) in USD $48.34
United States of America Life Sciences Industry PB Ratio Median Figure of 36 Publicly-Listed Life Sciences Companies 4.52x
United States of America Market PB Ratio Median Figure of 5,066 Publicly-Listed Companies 1.74x
NasdaqGS:BRKR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BRKR Share Price ÷ Book Value per Share (both in USD)

= 48.34 ÷ 5.49

8.8x

* Primary Listing of Bruker.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bruker is overvalued based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess Bruker's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Bruker has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BRKR Future Performance

 How is Bruker expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bruker expected to grow at an attractive rate?
  • Bruker's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Bruker's earnings growth is expected to exceed the United States of America market average.
  • Bruker's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:BRKR Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:BRKR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 14.3%
NasdaqGS:BRKR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 4.9%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 17.8%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:BRKR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:BRKR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 2,469 1
2022-12-31 2,390 2
2021-12-31 2,256 342 283 7
2020-12-31 2,150 300 250 10
2019-12-31 2,046 286 215 9
2019-11-12
NasdaqGS:BRKR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 2,026 210 207
2019-06-30 1,972 185 189
2019-03-31 1,925 210 184
2018-12-31 1,896 240 180
2018-09-30 1,873 211 98
2018-06-30 1,842 219 92
2018-03-31 1,813 166 84
2017-12-31 1,766 154 79
2017-09-30 1,706 142 151
2017-06-30 1,664 142 161
2017-03-31 1,621 177 152
2016-12-31 1,611 131 154

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Bruker's earnings are expected to grow by 14.3% yearly, however this is not considered high growth (20% yearly).
  • Bruker's revenue is expected to grow by 4.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:BRKR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Bruker Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:BRKR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 1.82 2.01 1.67 3.00
2020-12-31 1.63 1.78 1.48 4.00
2019-12-31 1.37 1.42 1.33 4.00
2019-11-12
NasdaqGS:BRKR Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 1.33
2019-06-30 1.21
2019-03-31 1.17
2018-12-31 1.15
2018-09-30 0.63
2018-06-30 0.59
2018-03-31 0.53
2017-12-31 0.50
2017-09-30 0.95
2017-06-30 1.00
2017-03-31 0.94
2016-12-31 0.95

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Bruker is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Bruker's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bruker has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BRKR Past Performance

  How has Bruker performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bruker's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bruker's year on year earnings growth rate has been positive over the past 5 years.
  • Bruker's 1-year earnings growth exceeds its 5-year average (110.5% vs 19.1%)
  • Bruker's earnings growth has exceeded the US Life Sciences industry average in the past year (110.5% vs 37.2%).
Earnings and Revenue History
Bruker's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bruker Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:BRKR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 2,026.30 206.70 490.70 185.80
2019-06-30 1,971.80 188.80 472.20 181.50
2019-03-31 1,925.30 183.50 458.40 176.60
2018-12-31 1,895.60 179.70 448.60 173.40
2018-09-30 1,872.50 98.20 443.10 171.70
2018-06-30 1,841.50 91.80 439.80 170.50
2018-03-31 1,812.70 84.00 432.20 167.20
2017-12-31 1,765.90 78.60 420.00 161.60
2017-09-30 1,705.70 151.00 406.60 156.70
2017-06-30 1,664.00 160.50 399.30 154.00
2017-03-31 1,620.80 151.60 395.90 150.50
2016-12-31 1,611.30 153.60 394.40 147.90
2016-09-30 1,619.20 146.00 393.40 147.50
2016-06-30 1,621.40 111.30 392.70 143.90
2016-03-31 1,645.70 118.70 390.30 144.60
2015-12-31 1,623.80 101.60 392.20 145.70
2015-09-30 1,653.60 66.30 407.70 150.60
2015-06-30 1,677.30 60.00 419.60 158.40
2015-03-31 1,738.70 54.50 436.10 165.40
2014-12-31 1,808.90 56.70 451.00 174.20
2014-09-30 1,853.00 65.80 450.80 181.70
2014-06-30 1,872.20 76.90 448.50 185.10
2014-03-31 1,869.70 83.40 440.60 187.10
2013-12-31 1,839.40 80.10 437.90 190.50
2013-09-30 1,804.60 57.70 443.60 191.70
2013-06-30 1,813.40 80.80 439.30 191.10
2013-03-31 1,779.20 67.80 442.80 196.50
2012-12-31 1,791.40 77.50 440.40 195.30

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Bruker has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Bruker used its assets more efficiently than the US Life Sciences industry average last year based on Return on Assets.
  • Bruker has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Bruker's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bruker has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BRKR Health

 How is Bruker's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bruker's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bruker is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bruker's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bruker's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bruker Company Filings, last reported 1 month ago.

NasdaqGS:BRKR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 875.60 517.50 302.40
2019-06-30 892.10 493.20 288.80
2019-03-31 943.60 334.20 298.80
2018-12-31 927.70 341.10 322.40
2018-09-30 825.20 240.60 270.10
2018-06-30 785.30 220.60 258.70
2018-03-31 790.30 220.60 283.90
2017-12-31 733.50 414.30 439.20
2017-09-30 739.90 480.50 429.20
2017-06-30 763.10 430.80 440.30
2017-03-31 731.60 384.80 464.50
2016-12-31 693.10 411.70 500.30
2016-09-30 700.90 364.90 441.50
2016-06-30 670.40 343.00 420.40
2016-03-31 709.10 302.20 420.50
2015-12-31 732.90 265.80 468.30
2015-09-30 768.00 371.40 532.30
2015-06-30 767.50 364.60 493.60
2015-03-31 721.60 354.60 492.30
2014-12-31 771.70 355.00 497.50
2014-09-30 813.10 355.20 442.30
2014-06-30 885.40 355.70 457.60
2014-03-31 868.30 354.80 454.00
2013-12-31 850.20 355.00 438.70
2013-09-30 780.60 355.70 306.80
2013-06-30 722.70 336.50 250.90
2013-03-31 692.60 336.60 269.40
2012-12-31 709.70 337.20 310.60
  • Bruker's level of debt (59.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (43.7% vs 59.1% today).
  • Debt is well covered by operating cash flow (40.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 20.2x coverage).
X
Financial health checks
We assess Bruker's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bruker has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BRKR Dividends

 What is Bruker's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.33%
Current annual income from Bruker dividends. Estimated to be 0.33% next year.
If you bought $2,000 of Bruker shares you are expected to receive $7 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Bruker's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.42%).
  • Bruker's dividend is below the markets top 25% of dividend payers in United States of America (3.67%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:BRKR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1948 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:BRKR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.16 1.00
2020-12-31 0.16 2.00
2019-12-31 0.16 2.00
2019-11-12
NasdaqGS:BRKR Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-08-12 0.160 0.367
2019-05-10 0.160 0.352
2019-02-15 0.160 0.413
2018-11-09 0.160 0.495
2018-08-13 0.160 0.479
2018-05-14 0.160 0.520
2018-02-20 0.160 0.530
2017-11-13 0.160 0.468
2017-08-14 0.160 0.534
2017-05-12 0.160 0.572
2017-02-21 0.160 0.678
2016-11-14 0.160 0.704
2016-08-09 0.160 0.730
2016-05-17 0.160 0.656
2016-02-22 0.160 0.575

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bruker is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.
  • Bruker is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Bruker's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Bruker's dividends as it is not paying a notable one for United States of America.
Future Payout to shareholders
  • No need to calculate the sustainability of Bruker's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Bruker's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bruker afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bruker has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BRKR Management

 What is the CEO of Bruker's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Frank Laukien
COMPENSATION $4,479,899
AGE 59
TENURE AS CEO 28.8 years
CEO Bio

Dr. Frank H. Laukien, Ph.D., has been the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Executive Officer and President of Bruker BioSpin Corporation. He served as the Chairman, President and Chief Executive Officer of Bruker Daltonics Inc. since February 1991. He served as Chief Executive Officer and President of Bruker BioSciences. He served as the President of Bruker BioSpin Corporation since June 1997 and served as its Co-Chief Executive Officer. He served as the Co-Chief Executive Officer of the worldwide Bruker BioSpin family of companies since December 2002. He served as the Chief Executive Officer of Bruker AXS Inc. from October 1997 to March 2000 and its Executive Chairman from October 1997 to July 2003. Dr. Laukien has been a Director of Bruker BioSciences Corp. since June 1997. He has been a Director of Bruker Corporation since February 1991. He has been a Director of Bruker Energy & Supercon Technologies, Inc. since April 2008. He has been Director of Bruker BioSpin Corporation since June 1997. He served as a Director of Bruker AXS Inc. from October 1997 to March 2000. He is a part-time professor at the Swammerdam Institute for Life Sciences (SILS) of the University of Amsterdam. In November 2001, he was elected an officer and Chairman-Elect of ALSSA (Analytical & Life Science Systems Association), an industry organization. He is a Trustee of the Rivers School in Weston, MA. Throughout his 20 year business career, he has taken numerous courses and done extensive reading in business, innovation and R&D management, accounting and corporate finance as well as in business, corporate and IP law. Dr. Laukien holds a B.S. in physics from the Massachusetts Institute of Technology and a Ph.D. in chemical physics from Harvard University.

CEO Compensation
  • Frank's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Frank's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Bruker management team in years:

9.6
Average Tenure
61
Average Age
  • The average tenure for the Bruker management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Frank Laukien

TITLE
Chairman
COMPENSATION
$4M
AGE
59
TENURE
28.8 yrs

Gerald Herman

TITLE
CFO, VP & Corporate Controller
COMPENSATION
$1M
AGE
61
TENURE
1.7 yrs

Mark Munch

TITLE
Executive VP and President of Bruker Nano Group & Bruker Nano Surfaces Division
COMPENSATION
$2M
AGE
57
TENURE
4.3 yrs

Juergen Srega

TITLE
President of Bruker CALID Group & Bruker Daltonics Division
COMPENSATION
$1M
AGE
64
TENURE
6.8 yrs

Falko Busse

TITLE
President of Bruker BioSpin Group
COMPENSATION
$1M
AGE
52
TENURE
1.5 yrs

Miroslava Minkova

TITLE
Director of Investor Relations & Corporate Development

Richard Stein

TITLE
Secretary
COMPENSATION
$16K
AGE
67
TENURE
19.8 yrs

Collin D’Silva

TITLE
President of Chemical Analysis Division
COMPENSATION
$1M
AGE
62
TENURE
9.6 yrs

Stacey Desrochers

TITLE
Treasurer & Director of Investor Relations
TENURE
11.7 yrs

Urban Faeh

TITLE
President of Bruker Optics Division
TENURE
9.8 yrs
Board of Directors Tenure

Average tenure and age of the Bruker board of directors in years:

4.5
Average Tenure
61.5
Average Age
  • The tenure for the Bruker board of directors is about average.
Board of Directors

Frank Laukien

TITLE
Chairman
COMPENSATION
$4M
AGE
59
TENURE
28.8 yrs

Richard Packer

TITLE
Independent Director
COMPENSATION
$216K
AGE
61
TENURE
12.5 yrs

Marc Kastner

TITLE
Independent Director
COMPENSATION
$192K
AGE
73
TENURE
4.8 yrs

John Ornell

TITLE
Independent Director
COMPENSATION
$218K
AGE
61
TENURE
4.3 yrs

William Linton

TITLE
Lead Director
COMPENSATION
$198K
AGE
71
TENURE
15.7 yrs

Gilles Martin

TITLE
Independent Director
COMPENSATION
$185K
AGE
56
TENURE
5.8 yrs

Hermann Requardt

TITLE
Independent Director
COMPENSATION
$193K
AGE
64
TENURE
4.3 yrs

Bob Rosenthal

TITLE
Independent Director
COMPENSATION
$203K
AGE
62
TENURE
4 yrs

Cynthia Friend

TITLE
Independent Director
COMPENSATION
$190K
AGE
64
TENURE
3.5 yrs

Adelene Perkins

TITLE
Independent Director
COMPENSATION
$201K
AGE
59
TENURE
2.5 yrs
Who owns this company?
Recent Insider Trading
  • Bruker individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
07. Nov 19 Sell Marc Kastner Individual 07. Nov 19 07. Nov 19 -3,203 $47.39 $-151,776
03. Jun 19 Sell Frank Laukien Individual 03. Jun 19 03. Jun 19 -400,000 $41.48 $-16,591,200
31. May 19 Sell Frank Laukien Individual 29. May 19 30. May 19 -400,000 $42.31 $-16,591,541
17. May 19 Sell Marc Kastner Individual 15. May 19 15. May 19 -1,374 $41.79 $-57,413
X
Management checks
We assess Bruker's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bruker has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BRKR News

Simply Wall St News

Is Bruker's (NASDAQ:BRKR) 115% Share Price Increase Well Justified?

One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. … During five years of share price growth, Bruker achieved compound earnings per share (EPS) growth of 21% per year. … It is important to consider the total shareholder return, as well as the share price return, for any given stock.

Simply Wall St -

These Factors Make Bruker Corporation (NASDAQ:BRKR) An Interesting Investment

In the case of BRKR, it is a company with great financial health as well as a an impressive history of performance. … This implies that BRKR manages its cash and cost levels well, which is an important determinant of the company’s health. … The intrinsic value infographic in our free research report helps visualize whether BRKR is currently mispriced by the market.

Simply Wall St -

Does Bruker Corporation's (NASDAQ:BRKR) CEO Pay Compare Well With Peers?

At the time of writing our data says that Bruker Corporation has a market cap of US$6.4b, and is paying total annual CEO compensation of US$4.5m. … A first glance this seems like a real positive for shareholders, since Frank Laukien is paid less than the average total compensation paid by similar sized companies. … It looks like Bruker Corporation pays its CEO less than similar sized companies.

Simply Wall St -

Does Bruker Corporation's (NASDAQ:BRKR) August Stock Price Reflect Its Future Growth?

Bruker Corporation (NASDAQ:BRKR) is considered a high-growth stock, but its last closing price of $41.57 left some investors wondering if this high future earnings potential can be rationalized by its current price tag. … This tells us that Bruker is overvalued compared to the US market average ratio of 17.55x , and overvalued based on current earnings compared to the Life Sciences industry average of 33.57x. … NasdaqGS:BRKR Price Estimation Relative to Market, August 5th 2019 We understand BRKR seems to be overvalued based on its current earnings, compared to its industry peers.

Simply Wall St -

How To Take Advantage Of Bruker Corporation (NASDAQ:BRKR) In A Bear Market

I'm talking about the well-proven, robust track record Bruker Corporation. … This consistent market outperformance illustrates a robust track record of delivering strong returns over a number of years, increasing my conviction in Bruker as an investment over the long run. … Next Steps: Bruker makes for a robust long-term investment based on its scale, financial health and track record.

Simply Wall St -

Here's Why Bruker (NASDAQ:BRKR) Can Manage Its Debt Responsibly

Why Does Debt Bring Risk? … Over the most recent three years, Bruker recorded free cash flow worth 58% of its EBIT, which is around normal, given free cash flow excludes interest and tax. … While debt does bring risk, when used wisely it can also bring a higher return on equity.

Simply Wall St -

Should You Be Excited About Bruker Corporation's (NASDAQ:BRKR) 20% Return On Equity?

The formula for return on equity is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Bruker: 20% = US$184m ÷ US$944m (Based on the trailing twelve months to March 2019.) It's easy to understand the 'net profit' part of that equation, but 'shareholders' equity' requires further explanation. … Bruker's Debt And Its 20% ROE Although Bruker does use debt, its debt to equity ratio of 0.35 is still low. … Judicious use of debt to improve returns can certainly be a good thing, although it does elevate risk slightly and reduce future optionality.

Simply Wall St -

Should You Be Tempted To Sell Bruker Corporation (NASDAQ:BRKR) Because Of Its P/E Ratio?

The formula for P/E is: Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS) Or for Bruker: P/E of 41.42 = $48.6 ÷ $1.17 (Based on the year to March 2019.) Is A High Price-to-Earnings Ratio Good? … Hypothetically, a company could reduce its future P/E ratio by spending its cash (or taking on debt) to achieve higher earnings. … Spending on growth might be good or bad a few years later, but the point is that the P/E ratio does not account for the option (or lack thereof).

Simply Wall St -

Is Now The Time To Put Bruker (NASDAQ:BRKR) On Your Watchlist?

But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' In the age of tech-stock blue-sky investing, my choice may seem old fashioned; I still prefer profitable companies like Bruker (NASDAQ:BRKR). … Although Bruker certainly looks good to me, I would like it more if insiders were buying up shares. … If you like to see insider buying, too, then this free list of growing companies that insiders are buying, could be exactly what you're looking for.

Simply Wall St -

Have Insiders Been Selling Bruker Corporation (NASDAQ:BRKR) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Bruker Corporation (NASDAQ:BRKR). … Does Bruker Boast High Insider Ownership? … Bruker insiders own about US$2.3b worth of shares (which is 34% of the company).

Simply Wall St -

BRKR Company Info

Description

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves pharmaceutical, biotechnology, and diagnostics companies; chemical, food and beverage, clinical, and polymer companies; nonprofit laboratories; contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensics, environmental and clinical microbiology laboratories, and hospitals and government departments and agencies, as well as agriculture, and food and beverage safety companies; nanotechnology, semiconductor, and industrial companies; and raw material manufacturers and other businesses through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Details
Name: Bruker Corporation
BRKR
Exchange: NasdaqGS
Founded: 1991
$7,443,956,070
153,991,644
Website: http://www.bruker.com
Address: Bruker Corporation
40 Manning Road,
Billerica,
Massachusetts, 01821,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BRKR Common Shares Nasdaq Global Select US USD 04. Aug 2000
DB BKD Common Shares Deutsche Boerse AG DE EUR 04. Aug 2000
BMV BRKR * Common Shares Bolsa Mexicana de Valores MX MXN 04. Aug 2000
Number of employees
Current staff
Staff numbers
6,870
Bruker employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/12 23:32
End of day share price update: 2019/11/12 00:00
Last estimates confirmation: 2019/11/06
Last earnings filing: 2019/11/04
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.